Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Letter to the editor on " Survivorship of a modular acetabular cup system: medium- to long-term follow-up".

Egilman DS, Steffen JE, Fassler EA, Reardon KJ.

Arthroplast Today. 2018 Aug 6;4(3):392-393. doi: 10.1016/j.artd.2018.05.006. eCollection 2018 Sep. No abstract available.

2.

Use of Anti-Warnings to Falsely Reassure Downstream Users: An Asbestos Example.

Egilman D, Bird T, Wilson R.

New Solut. 2018 Nov;28(3):515-538. doi: 10.1177/1048291118794198. Epub 2018 Aug 20.

PMID:
30126335
3.

Commentary on "Assessment of Health Risk From Historical Use of Cosmetic Talcum Powder".

Egilman D, Steffen J.

New Solut. 2018 Nov;28(3):400-409. doi: 10.1177/1048291118794166. Epub 2018 Aug 19.

PMID:
30122133
4.
5.

Correspondence regarding the article "The asbestos fibre burden in human lungs: new insights into the chrysotile debate".

Oliver LC, Belpoggi F, Budnik LT, Egilman D, Frank AL, Mandrioli D, Soskolne CL, Terracini B, Welch L, Baur X.

Eur Respir J. 2017 Dec 21;50(6). pii: 1701644. doi: 10.1183/13993003.01644-2017. Print 2017 Dec. No abstract available.

PMID:
29269580
6.

Grave fraudulence in medical device research: a narrative review of the PIN seeding study for the Pinnacle hip system.

Steffen JE, Fassler EA, Reardon KJ, Egilman DS.

Account Res. 2018;25(1):37-66. doi: 10.1080/08989621.2017.1405259.

PMID:
29258356
7.

Response to Hessel.

Egilman D.

Am J Ind Med. 2017 Oct;60(10):915-920. doi: 10.1002/ajim.22773. No abstract available.

PMID:
28925565
8.

Asbestos, asbestosis, and cancer: The Helsinki criteria for diagnosis and attribution. Critical need for revision of the 2014 update.

Baur X, Woitowitz HJ, Budnik LT, Egilman D, Oliver C, Frank A, Soskolne CL, Landrigan PJ, Lemen RA.

Am J Ind Med. 2017 May;60(5):411-421. doi: 10.1002/ajim.22709. No abstract available.

PMID:
28409857
9.

Corporate corruption of science-Another asbestos example.

Egilman D, Monárrez R.

Am J Ind Med. 2017 Feb;60(2):152-162. doi: 10.1002/ajim.22686.

PMID:
28079278
10.

Unreliable proposed 'new standard' for assessing asbestos exposure.

Egilman D, Baur X, Soskolne CL.

Occup Environ Med. 2016 Oct;73(10):709. doi: 10.1136/oemed-2016-103704. Epub 2016 Jul 27. No abstract available.

PMID:
27466612
11.

A commentary on Roggli's "The So-Called Short-Fiber Controversy".

Egilman D, Tran T.

Int J Occup Environ Health. 2016 Jul;22(3):181-186. doi: 10.1080/10773525.2016.1153866. Epub 2016 May 24.

12.

Short fiber tremolite free chrysotile mesothelioma cohort revealed.

Egilman D, Bird T.

Am J Ind Med. 2016 Mar;59(3):196-9. doi: 10.1002/ajim.22552. Epub 2016 Jan 4.

PMID:
26725926
13.

Ethics, morality, and conflicting interests: how questionable professional integrity in some scientists supports global corporate influence in public health.

Baur X, Budnik LT, Ruff K, Egilman DS, Lemen RA, Soskolne CL.

Int J Occup Environ Health. 2015;21(2):172-5. doi: 10.1179/2049396714Y.0000000103. Epub 2015 Mar 2.

14.

Dust diseases and the legacy of corporate manipulation of science and law.

Egilman D, Bird T, Lee C.

Int J Occup Environ Health. 2014 Apr-Jun;20(2):115-25. doi: 10.1179/1077352514Z.000000000104. Epub 2014 Mar 4.

15.

Workers and consumers should not be exposed to chemicals that have not been tested for toxicity.

Egilman DS.

Am J Ind Med. 2014 Aug;57(8):970-1. doi: 10.1002/ajim.22343. Epub 2014 Jun 25. No abstract available.

PMID:
24965179
16.

Egilman and Schilling respond.

Egilman D, Schilling JH.

Int J Occup Environ Health. 2014 Jan-Mar;20(1):6-8. No abstract available.

17.

MetLife and its corporate allies: dust diseases and the manipulation of science.

Egilman DS, Bird T, Lee C.

Int J Occup Environ Health. 2013 Oct-Dec;19(4):287-303.

PMID:
24588035
18.

Commentary on 'evaluation of take home (para-occupational) exposure to asbestos and disease: a review of the literature', Donovan et al.1.

Egilman DS, Druar NM.

Int J Occup Environ Health. 2013 Jul-Sep;19(3):163-8. doi: 10.1179/1077352513Z.00000000072. No abstract available.

PMID:
23885770
19.

The importance of scientific debate.

Egilman DS.

Int J Occup Environ Health. 2013 Jul-Sep;19(3):157-9. doi: 10.1179/1077352513Z.00000000076. No abstract available.

PMID:
23885768
20.

Statement in response to asbestos industry efforts to prevent a ban on asbestos in Pakistan: chrysotile asbestos use is not safe and must be banned.

Aguilar Madrid G, Beaudry M, Bell W, Bowes D, Brophy J, Burdorf A, Carlsten C, Castleman B, Chaturvedi S, Conti ME, Corra L, Corrêa Filho HR, Cranor CF, Cullen E, Dalvie A, Dickson RC, Digon A, Egilman D, Eisner Falvo C, Fischer E, Frank AL, Frank E, Gee D, Giannasi F, Goldstein BD, Greenberg M, Guidotti TL, Harris WA, Hindry M, Houlson A, Hu H, Huff J, Infante PF, Thambyappa J, Juarez Perez CA, Jeebhay MF, Joshi TK, Keith M, Keyserlingk JR, Khatter K, King D, Kodeih N, Kristensen J, Kulsomboon V, Landrigan PJ, Lee CW, Leigh J, Lemen RA, Lippman A, London L, Matzopoulos R, McCulloch J, McDiarmid MA, Mehrdad R, Mirabelli D, Moshammer H, Notebaert É, Nycz Z, Oberta AF, O'Connor J, O'Neill R, Orris P, Ozonoff D, Paek D, Rickard C, Rodriguez EJ, Sass J, Sentes KE, Simpson IM, Soffritti M, Soskolne CL, Sparling SP, Spiegel J, Takahashi K, Takaro TK, Terracini B, Thébaud-Mony A, Trosic I, Turcotte F, Vakil C, Van Der Walt A, Waterman YR, Watterson A, Wegman DH, Welch LS, Weiss SH, Winston R, Yassi A.

Arch Environ Occup Health. 2013;68(4):243-9. doi: 10.1080/19338244.2013.780807. No abstract available.

PMID:
23697697
21.

Bronchiolitis obliterans and consumer exposure to butter-flavored microwave popcorn: a case series.

Egilman DS, Schilling JH.

Int J Occup Environ Health. 2012 Jan-Mar;18(1):29-42.

PMID:
22550695
22.

Spin your science into gold: direct to consumer marketing within social media platforms.

Egilman D, Druar NM.

Work. 2012;41 Suppl 1:4494-502. doi: 10.3233/WOR-2012-0751-4494. Review.

PMID:
22317414
23.

Report of a recent "brake" through in the fiber burden-mesothelioma dialogue.

Egilman D.

Inhal Toxicol. 2012;24(2):136-7. doi: 10.3109/08958378.2011.643932. No abstract available.

PMID:
22283446
24.

Letter to the Editor regarding the Donovan et al. (2011) article.

Egilman D, Schilling JH.

Crit Rev Toxicol. 2012 Feb;42(2):169-72; author reply 173-83. doi: 10.3109/10408444.2011.651011. No abstract available.

PMID:
22276592
25.

Deconstructing a state-of-the-art review of the asbestos brake industry.

Egilman DS, Ardolino EL, Howe S, Bird T.

New Solut. 2011;21(4):545-71. doi: 10.2190/NS.21.4.e.

PMID:
22202589
26.
27.

Medical schools in sub-Saharan Africa.

De Maeseneer J, Egilman D, Burdick WP, Kaufman A.

Lancet. 2011 Oct 8;378(9799):1294; author reply 1295. doi: 10.1016/S0140-6736(11)61570-5. No abstract available.

PMID:
21982093
28.

Tackling NCDs: a different approach is needed.

De Maeseneer J, Roberts RG, Demarzo M, Heath I, Sewankambo N, Kidd MR, van Weel C, Egilman D, Boelen C, Willems S.

Lancet. 2012 May 19;379(9829):1860-1. doi: 10.1016/S0140-6736(11)61135-5. Epub 2011 Sep 5. No abstract available.

PMID:
21899880
29.

Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial.

Krumholz SD, Egilman DS, Ross JS.

Arch Intern Med. 2011 Jun 27;171(12):1100-7. doi: 10.1001/archinternmed.2011.241.

30.

An elaboration of "proof" of peritoneal mesothelioma from tremolite free chrysotile.

Egilman D.

Am J Ind Med. 2011 Aug;54(8):647. doi: 10.1002/ajim.20975. Epub 2011 Jun 10. No abstract available.

PMID:
21671249
31.

Corporate versus public interests: community responsibility to defend scientific integrity.

Egilman DS, Druar NM.

Int J Occup Environ Health. 2011 Apr-Jun;17(2):181-5. No abstract available.

PMID:
21618951
32.

A proposal for a safe exposure level for diacetyl.

Egilman DS, Schilling JH, Menendez L.

Int J Occup Environ Health. 2011 Apr-Jun;17(2):122-34.

PMID:
21618944
33.

Small is not necessarily beautiful.

Egilman DS, Bohme S.

Int J Occup Environ Health. 2010 Oct-Dec;16(4):542-3. No abstract available.

PMID:
21222395
34.

Persistence of cardiovascular risk after rofecoxib discontinuation.

Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM.

Arch Intern Med. 2010 Dec 13;170(22):2035-6. doi: 10.1001/archinternmed.2010.461. No abstract available. Erratum in: Arch Intern Med. 2011 Feb 28;171(4):305.

35.

A case of occupational peritoneal mesothelioma from exposure to tremolite-free chrysotile in Quebec, Canada: A black swan case.

Egilman D, Menéndez LM.

Am J Ind Med. 2011 Feb;54(2):153-6. doi: 10.1002/ajim.20882. Epub 2010 Aug 18.

PMID:
20721899
36.

Scientists appeal to Quebec Premier Charest to stop exporting asbestos to the developing world.

Takaro TK, Davis D, Van Rensburg SJ, Arroyo Aguilar RS, Algranti E, Bailar JC 3rd, Belpoggi F, Berlin M, Bhattacharya S, Bonnier Viger YV, Brophy J, Bustinza R, Cameron RB, Dement JM, Egilman D, Castleman B, Chaturvedi S, Cherniack M, Choudhury H, Demers PA, Digangi J, Digon A, Edwards JG, Englund A, Erikson B, Corréa Filho HR, Franco G, Frank AL, Freund A, Gee D, Giordano A, Gochfeld M, Gilberg M, Goldsmith DF, Goldstein BD, Grandjean P, Greenberg M, Gut I, Harari R, Hindry M, Hogstedt C, Huff J, Infante PF, Järvholm B, Kern DG, Keifer M, Khatter K, Kjuus H, Keith M, Koo LC, Kumar A, LaDou J, Landrigan PJ, Lemen RA, Last JM, Lee CW, Leigh J, Levin SM, Lippman A, Madrid GA, McCulloch J, McDiarmid MA, Merchant JA, Monforton C, Morse T, Muir DC, Mukerjee D, Mulloy KB, Myers J, Nuwayhid I, Orris P, Ozonoff D, Paek D, Patra M, Pelclová D, Pepper L, Poje GV, Rahman Q, Reyes B, Robinson BW, Rodríguez E, Rose C, Rosenman KD, Rosenstock L, Ruchirawat M, Rydzyński K, Schneider J, Silverstein B, Siqueira CE, Slatin C, Soffritti M, Soskoline C, Sparer J, Stayner LT, Takaro TK, Tarkowski S, Teitelbaum DT, Tompa A, Trosic I, Turcotte F, Vilela RA, Waterman YR, Watterson A, Wegman DH, Welch LS, Woitowitz HJ, Yanri Z, Zavariz C.

Int J Occup Environ Health. 2010 Apr-Jun;16(2):241-8. No abstract available.

PMID:
20465068
37.

Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM.

Arch Intern Med. 2009 Nov 23;169(21):1976-85. doi: 10.1001/archinternmed.2009.394.

38.

Call for global health-systems impact assessments.

Swanson RC, Mosley H, Sanders D, Egilman D, De Maeseneer J, Chowdhury M, Lanata CF, Dearden K, Bryant M.

Lancet. 2009 Aug 8;374(9688):433-5. doi: 10.1016/S0140-6736(09)61212-5. Epub 2009 Jul 2. No abstract available.

PMID:
19577289
39.

Fiber types, asbestos potency, and environmental causation: a peer review of published work and legal and regulatory scientific testimony.

Egilman D.

Int J Occup Environ Health. 2009 Apr-Jun;15(2):202-28. Erratum in: Int J Occup Environ Health. 2009 Jul-Sep;15(3):248.

PMID:
19496487
40.

Ford, General Motors, Chrysler, asbestos, and a "sane appreciation of the risks".

Egilman D.

Int J Occup Environ Health. 2009 Jan-Mar;15(1):109-10. No abstract available.

PMID:
19267130
41.

Beyond reputation: debate on the role of corporate influence in occupational and environmental medicine.

Bohme SR, Egilman D.

New Solut. 2008;18(3):317-24. doi: 10.2190/NS.18.3.d.

PMID:
18826880
42.

The ADVANTAGE seeding trial: a review of internal documents.

Hill KP, Ross JS, Egilman DS, Krumholz HM.

Ann Intern Med. 2008 Aug 19;149(4):251-8. Review.

PMID:
18711155
43.

IJOEH and the critique of bias.

Egilman DS, Bohme SR.

Int J Occup Environ Health. 2008 Apr-Jun;14(2):147-51. No abstract available.

PMID:
18507293
44.

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.

Ross JS, Hill KP, Egilman DS, Krumholz HM.

JAMA. 2008 Apr 16;299(15):1800-12. doi: 10.1001/jama.299.15.1800.

PMID:
18413874
45.

Funding for primary health care in developing countries.

De Maeseneer J, van Weel C, Egilman D, Mfenyana K, Kaufman A, Sewankambo N, Flinkenflögel M.

BMJ. 2008 Mar 8;336(7643):518-9. doi: 10.1136/bmj.39496.444271.80. No abstract available.

46.

Strengthening primary care: addressing the disparity between vertical and horizontal investment.

De Maeseneer J, van Weel C, Egilman D, Mfenyana K, Kaufman A, Sewankambo N.

Br J Gen Pract. 2008 Jan;58(546):3-4. doi: 10.3399/bjgp08X263721. No abstract available.

47.

Letter to U.S. FDA commissioner. Questions about the safety of the artificial sweetener aspartame.

Abdo KM, Camargo CA Jr, Davis D, Egilman D, Epstein SS, Froines J, Hattis D, Hooper K, Huff J, Infante PF, Jacobson MF, Teitelbaum DT, Tickner JA.

Int J Occup Environ Health. 2007 Oct-Dec;13(4):449-50. No abstract available.

PMID:
18085059
48.

American College of Occupational and Environmental Medicine (ACOEM): a professional association in service to industry.

LaDou J, Teitelbaum DT, Egilman DS, Frank AL, Kramer SN, Huff J.

Int J Occup Environ Health. 2007 Oct-Dec;13(4):404-26. Review.

PMID:
18085054
49.

Manipulated data in Shell's Benzene Historical Exposure Study.

Egilman D, Scout, Kol L, Hegg LA, Bohme SR.

Int J Occup Environ Health. 2007 Apr-Jun;13(2):222-32.

PMID:
17718180
50.

Against anti-health epidemiology: corporate obstruction of public health via manipulation of epidemiology.

Egilman D, Howe S.

Int J Occup Environ Health. 2007 Jan-Mar;13(1):118-24.

PMID:
17427356

Supplemental Content

Loading ...
Support Center